Resources from the same session
Invited Discussant VP3_2021
Presenter: Pasi Jänne
Session: Virtual Plenary Debate
Resources:
Slides
Webcast
VP3_2021 - A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Presenter: Ross Soo
Session: Virtual Plenary Debate
Resources:
Abstract
Slides
Webcast
Invited Discussant VP7_2021
Presenter: Lisa Carey
Session: Virtual Plenary Debate
Resources:
Slides
Webcast
VP7_2021 - KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Presenter: Peter Schmid
Session: Virtual Plenary Debate
Resources:
Abstract
Slides
Webcast
VP2_2021 - Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
Presenter: Solange Peters
Session: Virtual Plenary Debate
Resources:
Abstract
Slides
Invited Discussant VP4_2021
Presenter: Rosalind Glasspool
Session: Virtual Plenary Debate
Resources:
Slides
Webcast
VP4_2021 - EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
Presenter: Krishnansu S Tewari
Session: Virtual Plenary Debate
Resources:
Abstract
Slides
Webcast